Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.22.1
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Basic and diluted numerator:        
Net loss attributable to iBio, Inc. $ (12,390) $ (7,661) $ (33,249) $ (23,323)
Preferred stock dividends - iBio CMO Preferred Tracking Stock 0 (64) (88) (195)
Net loss available to iBio, Inc. stockholders $ (12,390) $ (7,725) $ (33,337) $ (23,518)
Basic and diluted denominator:        
Weighted-average common shares outstanding - basic 218,096 215,539 217,986 188,493
Weighted-average common shares outstanding - diluted 218,096 215,539 217,986 188,493
Per share amount basic $ (0.06) $ (0.04) $ (0.15) $ (0.12)
Per share amount diluted $ (0.06) $ (0.04) $ (0.15) $ (0.12)